Treatment with TQ in FLT3‐ITD positive MV4‐11 AML cells and BCR‐ABL positive K562 CML cells led to a dose‐ and time‐dependent reduction in cell proliferation, significant downregulation of PI3K, Akt, and mTOR, and an increase in PTEN expression at both mRNA and protein levels. Here, AKT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.